Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Myocardial Revascularization Surgery: One or Two Internal-Thoracic-Artery Grafts?

Myocardial Revascularization SurgeryThe use of both internal thoracic (mammary) arteries for myocardial revascularization surgery might improve long-term outcomes, compared with the use of a single internal thoracic artery.

 

Patients scheduled for myocardial revascularization surgery (only multivessel procedures; combined valve procedures were excluded) were randomized to receive a single internal-thoracic-artery graft (internal thoracic artery for the anterior descending artery, other vessels with grafts from veins or the radial artery) or two internal-thoracic-artery grafts (other vessels with grafts from veins or the radial artery) in 28 cardiac surgical centers in 7 countries.

 

The primary endpoint was all-cause death at 10 years, and the secondary endpoint was a composite of all-cause death, acute myocardial infarction, or stroke. An interim analysis was prespecified at 5 years of follow-up and is reported in this summary.

 

A total of 3102 patients were enrolled; 1554 were randomized to receive a single internal-thoracic-artery graft and 1548 to receive a double internal-thoracic-artery graft.

 

At 5 years of follow-up, the mortality rate was 8.7% for patients in the double internal-thoracic-artery graft group and 8.4% for those in the single internal-thoracic-artery graft group (hazard ratio [HR]: 1.04; 95% confidence interval [CI]: 0.81 to 1.32; p = 0.77). The rate of the composite endpoint of all-cause death, infarction, and stroke was 12.2% vs. 12.7%, respectively (HR: 0.96; 95% CI: 0.79 to 1.17; p = 0.69).

 

Differences were indeed observed regarding the risk of sternal wound infection, which was higher among those receiving a double internal-thoracic-artery graft (3.5% vs. 1.9%; p = 0.005), and the need for sternal reconstruction (1.9% vs. 0.6%; p = 0.002).

 

Conclusion

Among patients undergoing myocardial revascularization surgery, there were no benefits at 5 years for those receiving double internal-thoracic-artery grafts when compared with those in which only the left internal thoracic artery was used. Sternal wound infections and the need for sternal reconstruction were significantly more frequent in patients receiving double internal-thoracic-artery grafts. Ten-year follow-up is ongoing, and benefits are yet to be seen.

 

Original title: Randomized Trial of Bilateral Versus Single Internal-Thoracic-Artery Grafts.

Reference: David P. Taggart et al. N Engl J Med. 2016 Nov 14. [Epub ahead of print].


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...